Quick Takeaways
- Simcere Zaiming, Inc. filed SCHEDULE 13G for NEXTCURE, INC. Common Stock, par value $0.001 per share (NXTC).
- Disclosed ownership: 13%.
- Date of event: 20 Jun 2025.
Quoteable Key Fact
"Simcere Zaiming, Inc. disclosed 13% ownership in NEXTCURE, INC. Common Stock, par value $0.001 per share (NXTC) on 20 Jun 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Simcere Zaiming, Inc. | 13% | 338,636 | 338,636 | 0 | /s/ Renhong Tang | Renhong Tang/Chief Executive Officer | |
| Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | 13% | 338,636 | 338,636 | 0 | /s/ Renhong Tang | Renhong Tang/Director and Attorney-in-Fact | |
| Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | 13% | 338,636 | 338,636 | 0 | /s/ Renhong Tang | Renhong Tang/Chief Executive Officer and Chairman of the Board of Directors | |
| Simcere Pharmaceutical Group Limited | 13% | 338,636 | 338,636 | 0 | /s/ Jinsheng Ren | Jinsheng Ren / Chief Executive Officer and Chairman of the Board of Directors | |
| Ren Jinsheng | 13% | 338,636 | 0 | 338,636 | /s/ Jinsheng Ren | Jinsheng Ren | |
| Tang Renhong | 13% | 338,636 | 0 | 338,636 | /s/ Renhong Tang | Renhong Tang |